[Clinical psychopharmacology in 1971].
D000661:Amphetamine / Q000009:adverse effects; D000928:Antidepressive Agents / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D002746:Chlorpromazine / Q000627:therapeutic use; D003604:Czechoslovakia; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D006213:Hallucinogens / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008094:Lithium / Q000627:therapeutic use; D008238:Lysergic Acid Diethylamide / Q000627:therapeutic use; D001523:Mental Disorders / Q000188:drug therapy*; D011605:Psychoses, Substance-Induced / Q000209:etiology; D012895:Sleep, REM; D013888:Thiothixene / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000627:therapeutic use
D000928:Antidepressive Agents; D000978:Antiparkinson Agents; D006213:Hallucinogens; D006993:Hypnotics and Sedatives; D014149:Tranquilizing Agents; D004295:Dihydroxyphenylalanine; D013888:Thiothixene; D008238:Lysergic Acid Diethylamide; D008094:Lithium; D000661:Amphetamine; D002746:Chlorpromazine
Klinická psychofarmakologie v roce 1971.